表紙
市場調查報告書
商品編碼
808261

血糖監測系統的全球市場(2012年∼2024年)

BLOOD GLUCOSE MONITORING MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 236 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球血糖監測系統市場在2019年到2024年間,預測將以11.88%的年複合成長率發展,到2019年成長到128億美元。

本報告提供全球血糖監測系統市場調查,市場概要,各種類、終端用戶、地區的市場規模的變化與預測,市場成長要素及阻礙因素,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查結果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各類型
    • 血糖自我測量儀
    • 持續血糖儀
  • 各終端用戶
    • 醫院
    • 個人
  • 各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第6章 市場指標

  • 第一型糖尿病的患者的變化與預測
  • 第二型糖尿病的患者的變化與預測

第7章 競爭情形

  • 企業簡介
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 企業佔有率分析
    • Roche
    • Johnson & Johnson
    • Abboott Diabetes Care
    • 其他

第8章 市場機會與未來展望

目錄
Product Code: 55927

The blood glucose monitoring market is expected to register a CAGR of 9.6% during the forecast period of 2021-2026. The market is estimated to reach a value of USD 27.2 billion by 2026, which is due to an increase in the usage of monitoring devices among the type-2 diabetes population. Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices. Obesity is also considered as one of the major factors contributing to the disease, primarily Type 2 diabetes. Also, other factors, such as technological innovations and advancements, give many conveniences in measuring blood glucose levels. One such advancement in monitoring the blood glucose level is established with continuous glucose monitoring devices. These devices help in the early detection of hypo and hyperglycemic conditions. This favor is expected to drive the market for glucose monitoring.

Key Market Trends

Glucometer consumables occupy highest market share

Although CGM is an advanced way for people living with diabetes to check glucose readings in real-time, SMBG is the most preferred device by the patients due to its economic affordability and less sophisticated usage when compared to CGM. The SBGM devices occupy more than 68% of the share in the blood glucose monitoring market. The growth in market volume and share of test strips are expected to be higher than that of glucose meters, because of the difference in use-case frequency. The average efficiency of the glucose meter ranges between six months to three years, whereas test strips are for one-time use. The introduction of new kinds of lancet devices that induce lesser pain to the users is expected to help the market's growth, as the acceptance rate is expected to rise during the forecast period.

North America is leading the market

In 2020, North America, especially the United States, held the largest share in the blood glucose monitoring market, due to the large patient pool and wide acceptance of advanced technologies followed by Europe, with moderate growth. As per the American Diabetes Association (ADA), in 2018, 34.2 million Americans, or 10.5% of the population, had diabetes. Nearly 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents. In the United States, there are new innovations from start-up companies having approximately 2.9 billion funding in diabetes industries, like Glooko, OneDrop, verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, Orgenesis, etc. and Companies joined together in diabetes field to bring new technologies are increasing the market in the forecasting period, for instance, In July 2020, Medtronic PLC and Tandem Diabetes Care Inc. announced that they entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes.

Competitive Landscape

The blood glucose monitoring market is highly fragmented, with few major manufacturers present in the market. Mergers and acquisitions among the players in the recent past helped the companies to strengthen their market presence. For example, In September 2020, Insulet Corporation, with its Omnipod Insulin Management System (Omnipod System), announced it is commercially launching its Omnipod DASH Insulin Management System (Omnipod DASH System) in additional countries. The Omnipod DASH System is now available in Sweden, Finland, Norway, and Denmark and will be offered in France, Belgium, Germany, Austria, Switzerland, and Israel in the coming weeks.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Self-monitoring blood glucose devices (Value and Volume, 2016 - 2026)
    • 5.1.1 By Component
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
  • 5.2 Continuous blood glucose monitoring devices (Value and Volume, 2016 - 2026)
    • 5.2.1 By Component
      • 5.2.1.1 Sensors
      • 5.2.1.2 Durables (Receivers and Transmitters)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (Value and Volume, 2016 - 2026)
      • 5.3.1.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.1.2 Continuous Glucose Monitoring devices
      • 5.3.1.1.2.1 By Component (Sensors and Receivers)
      • 5.3.1.2 Canada (Value and Volume, 2016 - 2026)
      • 5.3.1.2.1 Self-monitoring blood glucose devices
      • 5.3.1.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.1.2.2 Continuous Glucose Monitoring
      • 5.3.1.2.2.1 By Component (Sensors and Receivers)
      • 5.3.1.3 Rest of North America (Value and Volume, 2016 - 2026)
      • 5.3.1.3.1 Self-monitoring blood glucose devices
      • 5.3.1.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.1.3.2 Continuous Glucose Monitoring
      • 5.3.1.3.2.1 By Component (Sensors and Receivers)
    • 5.3.2 Europe
      • 5.3.2.1 France (Value and Volume, 2016 - 2026)
      • 5.3.2.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.2.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.1.2 Continuous Glucose Monitoring
      • 5.3.2.1.2.1 By Component (Sensors and Receivers)
      • 5.3.2.2 Germany (Value and Volume, 2016 - 2026)
      • 5.3.2.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.2.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.2.2 Continuous Glucose Monitoring
      • 5.3.2.2.2.1 By Component (Sensors and Receivers)
      • 5.3.2.3 Italy (Value and Volume, 2016 - 2026)
      • 5.3.2.3.1 Self-monitoring blood glucose devices
      • 5.3.2.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.3.2 Continuous Glucose Monitoring
      • 5.3.2.3.2.1 By Component (Sensors and Receivers)
      • 5.3.2.4 Spain (Value and Volume, 2016 - 2026)
      • 5.3.2.4.1 Self-monitoring blood glucose devices
      • 5.3.2.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.4.2 Continuous Glucose Monitoring
      • 5.3.2.4.2.1 By Component (Sensors and Receivers)
      • 5.3.2.5 United Kingdom (Value and Volume, 2016 - 2026)
      • 5.3.2.5.1 Self-monitoring blood glucose devices
      • 5.3.2.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.5.2 Continuous Glucose Monitoring
      • 5.3.2.5.2.1 By Component (Sensors and Receivers)
      • 5.3.2.6 Russia (Value and Volume, 2016 - 2026)
      • 5.3.2.6.1 Self-monitoring blood glucose devices
      • 5.3.2.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.6.2 Continuous Glucose Monitoring
      • 5.3.2.6.2.1 By Component (Sensors and Receivers)
      • 5.3.2.7 Rest of Europe (Value and Volume, 2016 - 2026)
      • 5.3.2.7.1 Self-monitoring blood glucose devices
      • 5.3.2.7.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.2.7.2 Continuous Glucose Monitoring
      • 5.3.2.7.2.1 By Component (Sensors and Receivers)
    • 5.3.3 Latin America
      • 5.3.3.1 Mexico (Value and Volume, 2016 - 2026)
      • 5.3.3.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.3.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.3.1.2 Continuous Glucose Monitoring
      • 5.3.3.1.2.1 By Component (Sensors and Receivers)
      • 5.3.3.2 Brazil (Value and Volume, 2016 - 2026)
      • 5.3.3.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.3.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.3.2.2 Continuous Glucose Monitoring
      • 5.3.3.2.2.1 By Component (Sensors and Receivers)
      • 5.3.3.3 Rest of Latin America (Value and Volume, 2016 - 2026)
      • 5.3.3.3.1 Self-monitoring Blood Glucose Devices
      • 5.3.3.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.3.3.2 Continuous Glucose Monitoring
      • 5.3.3.3.2.1 By Component (Sensors and Receivers)
    • 5.3.4 Asia-Pacific
      • 5.3.4.1 Japan (Value and Volume, 2016 - 2026)
      • 5.3.4.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.1.2 Continuous Glucose Monitoring
      • 5.3.4.1.2.1 By Component (Sensors and Receivers)
      • 5.3.4.2 South Korea (Value and Volume, 2016 - 2026)
      • 5.3.4.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.2.2 Continuous Glucose Monitoring
      • 5.3.4.2.2.1 By Component (Sensors and Receivers)
      • 5.3.4.3 China (Value and Volume, 2016 - 2026)
      • 5.3.4.3.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.3.2 Continuous Glucose Monitoring
      • 5.3.4.3.2.1 By Component (Sensors and Receivers)
      • 5.3.4.4 India (Value and Volume, 2016 - 2026)
      • 5.3.4.4.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.4.2 Continuous Glucose Monitoring
      • 5.3.4.4.2.1 By Component (Sensors and Receivers)
      • 5.3.4.5 Australia (Value and Volume, 2016 - 2026)
      • 5.3.4.5.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.5.2 Continuous Glucose Monitoring
      • 5.3.4.5.2.1 By Component (Sensors and Receivers)
      • 5.3.4.6 Vietnam (Value and Volume, 2016 - 2026)
      • 5.3.4.6.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.6.2 Continuous Glucose Monitoring
      • 5.3.4.6.2.1 By Component (Sensors and Receivers)
      • 5.3.4.7 Malaysia (Value and Volume, 2016 - 2026)
      • 5.3.4.7.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.7.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.7.2 Continuous Glucose Monitoring
      • 5.3.4.7.2.1 By Component (Sensors and Receivers)
      • 5.3.4.8 Indonesia (Value and Volume, 2016 - 2026)
      • 5.3.4.8.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.8.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.8.2 Continuous Glucose Monitoring
      • 5.3.4.8.2.1 By Component (Sensors and Receivers)
      • 5.3.4.9 Philippines (Value and Volume, 2016 - 2026)
      • 5.3.4.9.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.9.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.9.2 Continuous Glucose Monitoring
      • 5.3.4.9.2.1 By Component (Sensors and Receivers)
      • 5.3.4.10 Thailand (Value and Volume, 2016 - 2026)
      • 5.3.4.10.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.10.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.10.2 Continuous Glucose Monitoring
      • 5.3.4.10.2.1 By Component (Sensors and Receivers)
      • 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2016 - 2026)
      • 5.3.4.11.1 Self-monitoring Blood Glucose Devices
      • 5.3.4.11.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.4.11.2 Continuous Glucose Monitoring
      • 5.3.4.11.2.1 By Component (Sensors and Receivers)
    • 5.3.5 Middle-East and Africa
      • 5.3.5.1 Saudi Arabia (Value and Volume, 2016 - 2026)
      • 5.3.5.1.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.1.2 Continuous Glucose Monitoring
      • 5.3.5.1.2.1 By Component (Sensors and Receivers)
      • 5.3.5.2 Iran (Value and Volume, 2016 - 2026)
      • 5.3.5.2.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.2.2 Continuous Glucose Monitoring
      • 5.3.5.2.2.1 By Component (Sensors and Receivers)
      • 5.3.5.3 Egypt (Value and Volume, 2016 - 2026)
      • 5.3.5.3.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.3.2 Continuous Glucose Monitoring
      • 5.3.5.3.2.1 By Component (Sensors and Receivers)
      • 5.3.5.4 Oman (Value and Volume, 2016 - 2026)
      • 5.3.5.4.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.4.2 Continuous Glucose Monitoring
      • 5.3.5.4.2.1 By Component (Sensors and Receivers)
      • 5.3.5.5 South Africa (Value and Volume, 2016 - 2026)
      • 5.3.5.5.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.5.2 Continuous Glucose Monitoring
      • 5.3.5.5.2.1 By Component (Sensors and Receivers)
      • 5.3.5.6 Rest of Middle-East and Africa (Value and Volume, 2016 - 2026)
      • 5.3.5.6.1 Self-monitoring Blood Glucose Devices
      • 5.3.5.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
      • 5.3.5.6.2 Continuous Glucose Monitoring
      • 5.3.5.6.2.1 By Component (Sensors and Receivers)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes population (2016 - 2026)
  • 6.2 Type-2 Diabetes population (2016 - 2026)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche Holding AG
    • 7.1.3 LifeScan
    • 7.1.4 Dexcom Inc.
    • 7.1.5 Medtronic PLC
    • 7.1.6 Arkray Inc.
    • 7.1.7 Ascensia Diabetes Care
    • 7.1.8 Agamatrix Inc.
    • 7.1.9 Bionime Corporation
    • 7.1.10 Acon Laboratories Inc.
    • 7.1.11 Medisana AG
    • 7.1.12 Trivida Functional Medicine
    • 7.1.13 Rossmax International Ltd
    • 7.1.14 Senseonics
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Self-monitoring Blood Glucose Devices
      • 7.2.1.1 Abbott Diabetes Care
      • 7.2.1.2 Roche Holding AG
      • 7.2.1.3 LifeScan
      • 7.2.1.4 Others
    • 7.2.2 Continuous Glucose Monitoring Devices
      • 7.2.2.1 Dexcom Inc.
      • 7.2.2.2 Medtronic PLC
      • 7.2.2.3 Abbott Diabetes Care
      • 7.2.2.4 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS